Topic:

R&D

Latest Headlines

Latest Headlines

FDA greenlights first human study of Wearable Artificial Kidney

Months after clearing the Wearable Artificial Kidney for human clinical trials, the FDA gave medical researchers a green light to begin the first human study of the device in the United States.

Civitas, NeuroDerm, EyeGate to pursue IPO dreams, combined $165M on the line

Israel's NeuroDerm filed for a stock offering on the basis of its subcutaneous formulation for treating Parkinson's; Civitas, the developer of an inhaled formulation for the disease, is expected to debut on the Nasdaq Sept. 24; and EyeGate Pharmaceuticals, which employs low-voltage electrical current to deliver eye medication, also just filed for an IPO.

X-ray-triggered liposomes deliver precisely controlled cancer treatment

Combining chemotherapy and radiotherapy would be ideal for cancer treatment, but administering both at the same time can lead to unacceptable and often deadly levels of toxicity. Now researchers have developed liposomes that contain a chemotherapy drug activated by radiotherapy, offering both cancer-killing power and a targeted approach in a more controlled manner.

UPDATED: Bioresorbable stent developer Amaranth Medical initiates new clinical trial

Stent developer Amaranth Medical is launching the MEND-II clinical trial to test its Fortitude Sirolimus-Eluting Bioresorbable Scaffold, a sign that companies large and small are keenly the new treatment paradigm for coronary artery disease involving stents that disintegrate within the body after a couple of years.

Harvard researchers develop dialysis device to fight Ebola

Amid mounting industry pressure to unveil a therapy to counter the deadly Ebola outbreak, researchers are developing an innovative dialysis device that fights the disease by filtering blood.

Biotech R&D is changing. Don't get left behind

Over the last few years we've seen some big changes in the way some drugs are developed. What better time to host a new FierceBiotech executive panel discussion on current trends in late-stage development?

Quintiles homes in on small biotechs with new service offering

Quintiles, the world's largest CRO, is dialing up its focus on nascent drugmakers, launching a biotech-focused service offering designed to meet the particular needs of the industry's seedlings without losing them in the Big Pharma shuffle.

Evotec signs a Huntington's deal as diabetes project falls through

Risk-sharing researcher Evotec took a blow last week when partner Hyperion Therapeutics pulled the plug on a diabetes trial, but the German company is keeping things moving, expanding an agreement that will put it to work on treatments for Huntington's disease.

SRI teams up with Japan's Nobelpharma on gynecology drug

Nonprofit researcher SRI International has struck a deal with Japanese drugmaker Nobelpharma to collaborate on a new treatment for the painful gynecological disease endometriosis.

Alivira snaps up 60% stake in Turkey's Provet Veterinary Products

Alivira Animal Health, a joint venture between Shasun Pharmaceuticals and SeQuent Scientific, has grabbed a 60% stake in Turkey's Provet Veterinary Products.